CN114652846B - 酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法和应用 - Google Patents
酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法和应用 Download PDFInfo
- Publication number
- CN114652846B CN114652846B CN202210263422.2A CN202210263422A CN114652846B CN 114652846 B CN114652846 B CN 114652846B CN 202210263422 A CN202210263422 A CN 202210263422A CN 114652846 B CN114652846 B CN 114652846B
- Authority
- CN
- China
- Prior art keywords
- tpgs
- tumor
- organic solvent
- dox
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 51
- 229940002612 prodrug Drugs 0.000 title claims abstract description 26
- 239000000651 prodrug Substances 0.000 title claims abstract description 26
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 24
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 24
- 230000003834 intracellular effect Effects 0.000 title claims abstract description 20
- 230000008685 targeting Effects 0.000 title claims abstract description 20
- 229920000642 polymer Polymers 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims description 23
- 229940079593 drug Drugs 0.000 title claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 23
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 22
- 239000003960 organic solvent Substances 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 13
- 229910021641 deionized water Inorganic materials 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 150000004985 diamines Chemical class 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940041181 antineoplastic drug Drugs 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 229930003427 Vitamin E Natural products 0.000 abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 229940046009 vitamin E Drugs 0.000 abstract description 4
- 235000019165 vitamin E Nutrition 0.000 abstract description 4
- 239000011709 vitamin E Substances 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 41
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 20
- 239000000693 micelle Substances 0.000 description 20
- 229960004679 doxorubicin Drugs 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- HPZOOQSXPMEJBV-ODCFVKFUSA-N Tirilazad mesylate Chemical compound CS(O)(=O)=O.O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 HPZOOQSXPMEJBV-ODCFVKFUSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBJBKNOSA-N (7s,9s)-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC(N)C(O)C(C)O1 MWWSFMDVAYGXBV-FGBJBKNOSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101710180313 Protease 3 Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229940035756 doxorubicin injection Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3328—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
- C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法和应用,酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药,其特征是如式(I)所示:本发明的酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药通过在DOX表面引入亲水性高分子聚合物TPGS(TPGS为维生素E聚乙二醇琥珀酸酯的简写),提高DOX体内血液循环中稳定性;并将多个功能整合到一个系统中,能够针对不同的给药阶段作出不同的响应,显著提高DOX化疗的抗癌效果,降低其毒副作用。
Description
技术领域
本发明主要涉及药物技术领域,具体涉及一种酶敏感、肿瘤主动靶向以及胞内快速释药TPGS-GPLGVRGDGDEVD-DOX聚合物前药,以及其制备方法和应用。
背景技术
近年来,癌症已成为世界上导致人类死亡的重要原因,但传统抗癌药物普遍存在体内半衰期短、毒副作用大、选择性差的缺点,因此研发出能够对肿瘤微环境响应的、以及能够主动靶向肿瘤细胞的药物载体系统成为目前研究的热点。近些年来,为了进一步改善药物在肿瘤部位的药代动力学和累积、提高细胞对抗癌药物的摄取以及减少药物对机体的毒副作用,针对肿瘤独特微环境和肿瘤表面特有的受体,研究人员设计了多种酶敏感或主动靶向肿瘤细胞的纳米药物载体。但是传统的纳米药物载体也存在着一些弊端,例如虽然基于EPR效应设计的药物载体能够在肿瘤部位被动富集,但是药物载体不易穿透肿瘤组织,因此药物载体在设计时为了延长其在体内的循环时间,往往会使用聚乙二醇等对载体表面进行修饰,然而修饰聚乙二醇不利于药物的细胞内化,导致抗癌药物效果不佳。
阿霉素(Doxorubicin,简称DOX)是蒽环类广谱抗癌药物,是临床常用的一种抗肿瘤药物,但存在水溶性差、稳定性差、容易产生耐药性、毒副作用大等缺点,使其在临床应用上受到极大限制。
发明内容
本发明的目的克服现有技术的不足,提供酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药。
本发明的第二个目的是提供酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药的制备方法。
本发明的第三个目的是提供酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药在制备抗癌药物中的应用。
本发明的技术方案概述如下:
酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药,如式I所示:
其中n=23-364,优选n=76;简写为TPGS-GPLGVRGDGDEVD-DOX。
酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药的制备方法,包括如下步骤:
(1)将α-TOS、聚乙二醇二胺、NHS和DCC溶于二氯甲烷反应,通过0.45μm的有机膜过滤,在滤液中加入乙醚,有沉淀析出,离心,沉淀用去离子水透析,冷冻干燥得到TPGS-NH2;
(2)将TPGS-NH2、戊二酸、NHS、DCC溶于有机溶剂,室温下通入氮气反应,反应结束后,依次用有机溶剂和去离子水透析,冷冻干燥;得到TPGS-COOH;
其中:聚乙二醇二胺中聚乙二醇分子的聚合度n=23-364;
(3)将TPGS-COOH、NHS和DCC溶解于有机溶剂中,在室温下通入氮气反应,反应结束后,通过0.45μm的有机膜过滤,得到第二种滤液;将多肽GPLGVRGDGDEVD溶解于有机溶剂中,加入到第二种滤液中,在室温下反应,依次用有机溶剂和去离子水透析,冷冻干燥;得到TPGS-GPLGVRGDGDEVD;
(4)将TPGS-GPLGVRGDGDEVD、NHS、DCC,溶于有机溶剂中,室温下反应,反应结束后,通过0.45μm的有机膜过滤,得到第三种滤液;将DOX溶解于有机溶剂中,加入到第三种滤液中反应,通过0.45μm的有机膜过滤,得到第四种滤液,第四种滤液再依次用有机溶剂和去离子水透析,冷冻干燥,得到酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药TPGS-GPLGVRGDGDEVD-DOX;
所述α-TOS是α-生育酚琥珀酸酯的简写;
NHS是N-羟基琥珀酰亚胺的简写;
DCC是N,N'-二环己基碳二亚胺的简写;
TPGS-NH2是末端氨基化的维生素E聚乙二醇琥珀酸酯的简写;
TPGS-COOH是末端羧基化的维生素E聚乙二醇琥珀酸酯的简写;
DOX为阿霉素的简写。
所述有机溶剂为N,N-二甲基甲酰胺、四氢呋喃或二甲基亚砜。
所述聚乙二醇二胺中聚乙二醇分子的聚合度n=76。
酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药在制备抗癌药物中的应用。本发明的优点:
(1)本发明的酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药(简式如TPGS-GPLGVRGDGDEVD-DOX)通过在DOX表面引入亲水性高分子聚合物TPGS(TPGS为维生素E聚乙二醇琥珀酸酯的简写),提高DOX体内血液循环中稳定性;
(2)本发明的TPGS-GPLGVRGDGDEVD-DOX将多个功能整合到一个系统中,能够针对不同的给药阶段作出不同的响应,显著提高DOX化疗的抗癌效果,降低其毒副作用。
附图说明
图1为本发明TPGS-GPLGVRGDGDEVD-DOX的核磁共振氢谱图;
图2为实施例2制备的载DOX的抗肿瘤胶束透射电镜图;
图3为给药情况下小鼠的肿瘤体积变化;
图4为给药情况下小鼠的体重变化。
具体实施方式
各实施例中的:
NHS是N-羟基琥珀酰亚胺的简写;
DCC是N,N'-二环己基碳二亚胺的简写;
α-TOS是α-生育酚琥珀酸酯的简写;
TPGS-NH2是末端氨基化的维生素E聚乙二醇琥珀酸酯的简写;
TPGS-COOH是末端羧基化的维生素E聚乙二醇琥珀酸酯的简写;
DOX为阿霉素的简写;
TPGS-GPLGVRGDGDEVD-DOX为酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药的简写。
下面通过具体实施例对本发明作进一步的说明,但不以任何方式限制本发明,与该领域相关的普通人员,对本发明进行的一些非本质的调整和改进,仍属于本发明的保护范围。
以下实施例中:
α-生育酚琥珀酸酯,聚乙二醇二胺购自北京凯正联合医药有限公司,
NHS,DCC和盐酸阿霉素(简写DOX·HCL)购自北京华奉联博化学材料有限公司;
所用氨基酸购自上海吉尔生化;
多肽GPLGVRGDGDEVD)由本实验室按照固相法合成。
BALB/c小鼠(6周龄,雌性)购自斯贝福(北京)生物技术有限公司,饲养于中国医学科学放射医学研究所动物实验中心,SPF级别。所有动物都严格按照国家《实验动物管理条例》进行,并且遵循实验动物伦理保护章程。(批准号:SCXK(京)2014-0004)。
下面结合实施例对本发明作进一步说明。
实施例1
酶敏感、肿瘤主动靶向以及胞内快速释药功能聚合物前药的制备方法,其中的酶敏感、肿瘤主动靶向以及胞内快速释药功能聚合物前药的结构如式I所示:
式I简写为:TPGS-GPLGVRGDGDEVD-DOX表示,式I中的n为76。
具体的步骤为:
(1)将α-TOS,1mmol、聚乙二醇二胺(NH2-PEGn-NH2)1.2mmol,(其中聚乙二醇的聚合度n为76)、NHS,1.2mmol和DCC,1.2mmol溶于5mL二氯甲烷中,室温下反应48小时,通过0.45μm的有机膜过滤,在滤液中加入乙醚,有沉淀析出,离心,沉淀用去离子水透析,冷冻干燥得到TPGS-NH2;
(2)再称取TPGS-NH2,1mmol、戊二酸,1.2mmol、NHS,1.2mmol和DCC,1.2mmol;溶于5mL二甲基亚砜中,室温下通入氮气反应24小时后,反应结束后,依次用二甲基亚砜和去离子水透析,冷冻干燥;得到TPGS-COOH;
(3)将TPGS-COOH,1mmol、NHS,1.2mmol和DCC,1.2mmol溶于二甲基亚砜中,室温下通入氮气反应24小时,反应结束后,通过0.45μm的有机膜过滤,得到第二种滤液;将多肽GPLGVRGDGDEVD,1.2mmol溶解于5mL二甲基亚砜中,加入到第二种滤液中,在室温下反应24小时,依次用二甲基亚砜和去离子水透析,冷冻干燥;得到TPGS-GPLGVRGDGDEVD;
(4)将TPGS-GPLGVRGDGDEVD,1mmol、NHS,1.2mmol、DCC、1.2mmol,溶于二甲基亚砜中,室温下反应12小时,反应结束后,通过0.45μm的有机膜过滤,得到第三种滤液,将DOX,2mmol溶解于二甲基亚砜中,加入到第三种滤液中,55℃反应10小时,再在室温下搅拌12小时,通过0.45μm的有机膜过滤,得到第四种滤液,第四种滤液再依次用二甲基亚砜和去离子水透析,冷冻干燥,得到酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药TPGS-GPLGVRGDGDEVD-DOX。透析的透析袋(MWCO 3500)。
上述合成路线如下:
其中:TPGS中聚乙二醇的聚合度n为76,也可以在23-364之间选任一整数值。
通过核磁共振氢谱1H-NMR表征TPGS-GPLGVRGDGDEVD-DOX的结构,从图1可以看出化学位移3.65ppm为PEG中-CH2CH2O-特征峰,-CH3的化学位移位于1.04-1.25ppm、-NH-为5.94ppm,-CH2-为1.89-1.91ppm。0.81-0.85ppm为TPGS中甲基和亚甲基等特征峰所在位置,阿霉素中特征峰-CH2-分别在2.00-2.06ppm和3.21-3.25ppm。通过核磁检测特征峰的存在证明成功制备了TPGS-GPLGVRGDGDEVD-DOX(TPGS-GPLGVRGDGDEVD-DOX见式I)。
用N,N-二甲基甲酰胺、四氢呋喃替代本实施例中的二甲基亚砜,其它同本实施例,制备出酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药。
实施例2
载DOX的抗肿瘤胶束的制备方法:包括如下步骤:
称量实施例1制备的TPGS-GPLGVRGDGDEVD-DOX,10mg,取DOX,1mg于25mL圆底烧瓶中,加入2mL二氯甲烷为溶剂,超声30秒充分溶解,400r/min磁力搅拌30分钟后,把溶液转移到旋转蒸发仪中,旋转蒸发除去有机溶剂直至圆底烧瓶出现一层薄膜,加入2mL去离子水,超声5分钟,然后再磁力搅拌30分钟,转移至注射器,用0.45μm的滤膜过滤至离心管中,离心除去未形成胶束的原料,冷冻干燥得到载DOX的抗肿瘤胶束;整个过程需要在避光室温的环境下。
其透射电镜图如图2所示,图中给出的标尺为200nm。
TPGS-GPLGVRGDGDEVD-DOX与DOX重量比为也可以为(2:1),(4:1)或(5:1),按本实施例的步骤,制备出相应的载DOX的抗肿瘤胶束。
实施例3
为了更好地考察本发明在生物体内抑制恶性肿瘤方面的效果,在小鼠体内建立4T1乳腺癌移植模型,然后分别注射实施例2制备的载DOX的抗肿瘤胶束、临床中应用的阿霉素注射液和PBS。
具体方法和步骤:在BALB/c 6周龄雌性小鼠皮下接种4T1小鼠乳腺癌细胞,接种第7天后,当小鼠的肿瘤体积达到50~100mm3时,将小鼠随机分为3组,每组5只,每只剪耳标记,具体分组如下:
1.空白对照组(PBS组):尾静脉注射100μL的PBS;
2.阿霉素组:通过尾静脉注射100μL浓度为1mg/mL的DOX·HCl的溶液(溶剂为PBS);
3.实验组:通过尾静脉注射100μL实施例2制备的载DOX的抗肿瘤胶束(简称胶束)的溶液(溶剂为PBS),其中DOX当量浓度为1mg/mL。
从打药的当天记为第0天,每4天注射一次药,共给4次(0,4,8,12)。从第0天开始,每隔一天用电子天平称量小鼠的体重,并用游标卡尺测量小鼠肿瘤垂直方向上的两个直径,分别作为肿瘤的长和宽,按照公式V=L×W2/2计算肿瘤的体积(V表示肿瘤的体积,L代表肿瘤较长的直径,W代表肿瘤较短的直径);记录相关数据,判断不同药物对小鼠生长状况的影响及肿瘤的抑制作用;
在治疗期间,发现PBS组肿瘤生长快速;阿霉素组的小鼠肿瘤体积增长较PBS组生长稍慢,但体重下降明显,状态过差;实验组(胶束组)小鼠的肿瘤体积几乎不增长,停止给药后肿瘤也没有复发的迹象,实验过程中小鼠状态正常。第28天后,实验结束;
从治疗开始到治疗结束共28天,期间小鼠肿瘤体积变化如图3所示,小鼠体重变化如图4所示。治疗第28天处死PBS组、阿霉素组和实验组时,PBS组肿瘤体积增长了47.71倍,体重变化不明显;阿霉素组肿瘤体积增长了18.50倍,体重下降明显,说明该药物对生物体产生较大毒性;而实验组治疗28天时,肿瘤体积仅为初始体积的3.52倍,且小鼠体重变化不大,说明该药物抑制肿瘤生长的作用显著,对生物体正常组织的毒性小,安全性高。
本发明通过TPGS-GPLGVRGDGDEVD-DOX自组装形成胶束,制备胶束时通过游离DOX与TPGS-GPLGVRGDGDEVD-DOX的DOX之间的π-π堆积(π-πstacking)作用,将游离DOX通过物理方式包埋到胶束的疏水内核中,既能够由于分子间作用使其形成的胶束内核更加紧密,减少临界聚集浓度(CAC)并在注射时保持胶束结构,有利于胶束在生理条件下有较好的稳定性,又能够提高整个递送系统的载药量,提高治疗效果;
本发明利用TPGS冠层修饰胶束,能够延长药物在血液循环系统中的滞留时间,从而通过EPR效应更多地在肿瘤部位聚集;胶束暴露于肿瘤组织处高表达基质金属蛋白酶MMP2后,多肽序列GPLGVRGDGDEVD能够在G和V处被切断并脱掉TPGS外壳,胶束的尺寸快速减小;暴露出靶向RGD配体的肽序列(VRGDG),与肿瘤细胞表面过度表达的αvβ3受体结合,具有主动靶向肿瘤细胞的能力,能够增强细胞对胶束的摄取,胞内在激活的凋亡蛋白酶3作用下,剪切DEVD释放前药端DOX,从而将胶束中化学键合及物理包埋的DOX更多地在细胞内进行释放,表现出显著的肿瘤靶向作用,同时减少对生物体正常组织的毒副作用。
本发明通过上述实施例来说明本发明的酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法及应用,但本发明并不局限于上述实施例,即不意味着本发明必须依赖上述实施例才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明所选用原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (6)
1.酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药,其特征是如式(I)所示:
其中n=23-364,简写为TPGS-GPLGVRGDGDEVD-DOX。
2.根据权利要求1所述聚合物前药,其特征是所述n=76。
3.权利要求1或2的酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药的制备方法,其特征是包括如下步骤:
(1)将α-TOS、聚乙二醇二胺、NHS和DCC溶于二氯甲烷反应,通过0.45μm的有机膜过滤,在滤液中加入乙醚,有沉淀析出,离心,沉淀用去离子水透析,冷冻干燥得到TPGS-NH2;
(2)将TPGS-NH2、戊二酸、NHS、DCC溶于有机溶剂,室温下通入氮气反应,反应结束后,依次用有机溶剂和去离子水透析,冷冻干燥;得到TPGS-COOH;
其中:聚乙二醇二胺中聚乙二醇分子的聚合度n=23-364;
(3)将TPGS-COOH、NHS和DCC溶解于有机溶剂中,在室温下通入氮气反应,反应结束后,通过0.45μm的有机膜过滤,得到第二种滤液;将多肽GPLGVRGDGDEVD溶解于有机溶剂中,加入到第二种滤液中,在室温下反应,依次用有机溶剂和去离子水透析,冷冻干燥;得到TPGS-GPLGVRGDGDEVD;
(4)将TPGS-GPLGVRGDGDEVD、NHS、DCC,溶于有机溶剂中,室温下反应,反应结束后,通过0.45μm的有机膜过滤,得到第三种滤液;将DOX溶解于有机溶剂中,加入到第三种滤液中反应,通过0.45μm的有机膜过滤,得到第四种滤液,第四种滤液再依次用有机溶剂和去离子水透析,冷冻干燥,得到酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药,简写为:TPGS-GPLGVRGDGDEVD-DOX。
4.根据权利要求3所述的制备方法,其特征是所述有机溶剂为N,N-二甲基甲酰胺、四氢呋喃或二甲基亚砜。
5.根据权利要求3所述的制备方法,其特征是所述聚乙二醇二胺中聚乙二醇分子的聚合度n=76。
6.权利要求1或2的酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药在制备抗癌药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210263422.2A CN114652846B (zh) | 2022-03-17 | 2022-03-17 | 酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210263422.2A CN114652846B (zh) | 2022-03-17 | 2022-03-17 | 酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114652846A CN114652846A (zh) | 2022-06-24 |
CN114652846B true CN114652846B (zh) | 2024-01-09 |
Family
ID=82028920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210263422.2A Active CN114652846B (zh) | 2022-03-17 | 2022-03-17 | 酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114652846B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106461641A (zh) * | 2014-01-27 | 2017-02-22 | 新加坡国立大学 | 用于细胞成像和药物筛选的基于具有聚集诱导发射特征之荧光团的发光探针 |
CN107157928A (zh) * | 2017-05-18 | 2017-09-15 | 中国科学技术大学 | 一种基质金属蛋白酶响应性聚合物药物载体及其制备方法和应用 |
CN110201185A (zh) * | 2019-06-18 | 2019-09-06 | 天津工业大学 | 一种酶响应的TPGSn-Pep-DOX化合物及制备方法及应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010101627A2 (en) * | 2009-03-02 | 2010-09-10 | Massachusetts Institute Of Technology | Methods and systems for treatment and/or diagnosis |
US20200048634A1 (en) * | 2018-08-09 | 2020-02-13 | Washington University | Methods to modulate protein translation efficiency |
-
2022
- 2022-03-17 CN CN202210263422.2A patent/CN114652846B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106461641A (zh) * | 2014-01-27 | 2017-02-22 | 新加坡国立大学 | 用于细胞成像和药物筛选的基于具有聚集诱导发射特征之荧光团的发光探针 |
CN107157928A (zh) * | 2017-05-18 | 2017-09-15 | 中国科学技术大学 | 一种基质金属蛋白酶响应性聚合物药物载体及其制备方法和应用 |
CN110201185A (zh) * | 2019-06-18 | 2019-09-06 | 天津工业大学 | 一种酶响应的TPGSn-Pep-DOX化合物及制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
Wen Gao et al..《 Biomaterials.》.2012,第第33卷卷(第第14期期),第3710-3718页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114652846A (zh) | 2022-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8247383B2 (en) | Drug-carrier complexes and methods of use thereof | |
Ren et al. | Development of transferrin functionalized poly (ethylene glycol)/poly (lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma | |
CN102120036B (zh) | 生物降解的高分子键合Pt(IV)类抗癌药物纳米胶束及其制备方法 | |
CN101254309A (zh) | 叶酸受体介导靶向乙酰普鲁兰多糖纳米粒及制备方法 | |
EP2322227A1 (en) | Ph-sensitive dendritic polymeric micelles | |
CN107184987B (zh) | 一种硫辛酸修饰的靶向整合素αvβ3纳米多肽载体及其制备方法和应用 | |
WO2001010468A2 (en) | Drug-carrier complexes and methods of use thereof | |
KR20180120220A (ko) | 난소암을 특이적으로 표적하는 생분해성 양친성 폴리머, 이로부터 제조된 폴리머 배시클 및 용도 | |
KR102279429B1 (ko) | 멀티 암 표적 항암 콘쥬게이트 | |
CN107266384B (zh) | 基于2-氨基十六烷酸的n-羧基内酸酐单体和聚氨基酸及其制备方法 | |
CN101007174A (zh) | 一种生物降解高分子-多西紫杉醇键合药及其制备方法 | |
CN109762099B (zh) | 一种聚合物-抗肿瘤药物偶联物及其制备方法和用途 | |
CN111743861B (zh) | 靶向三阴性乳腺癌的低氧响应手性药物胶束及其制备方法 | |
CN112121177B (zh) | 负载羧酸抗肿瘤药物的peg化肝素纳米胶束及其制备方法 | |
CN114652846B (zh) | 酶敏感、肿瘤主动靶向以及胞内快速释药的聚合物前药及制备方法和应用 | |
CN109662956B (zh) | 一种齐墩果酸接枝的壳聚糖载药纳米颗粒的应用 | |
CN109954144B (zh) | 基于改性聚β-氨基酯材料的双级pH响应纳米粒及其制备方法 | |
CN103055321A (zh) | 一种聚乙二醇单甲醚-聚磷酸酯两嵌段共聚物及其阿霉素键合药 | |
CN102652836A (zh) | 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法 | |
CN113398276B (zh) | 脑胶质瘤靶向小檗碱与叶酸修饰的脂质材料的制备与应用 | |
CN106432715B (zh) | 一种交替共聚物P(OE-alt-CL)的制备方法及其应用 | |
CN112546236B (zh) | 一种pH敏感的双药物骨架聚合物前药及其制备方法和应用 | |
CN104096237A (zh) | 一种Pluronics-紫杉醇两亲性大分子前药及其胶束制剂 | |
WO2007145455A1 (en) | Water soluble micelle-forming and biodegradable cyclotriphosphazene-taxol conjugate anticancer agent and preparation method thereof | |
CN107744503B (zh) | 酶敏感性两亲性聚酯MePEG-Peptide-PER-CL给药纳米粒的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |